Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
Our study first indicated in patients across all expression levels of HER2 that stable or at least once HER2-low status may confer favourable attributes including less malignant biological behaviour and long-term survival benefit for breast cancer receiving neoadjuvant therapy.
Authors
- Shuguang Xu (ORCID: https://orcid.org/0000-0003-0861-0754)
- Yumei Ye
- Xinru Chen
- Wenjin Yin (ORCID: https://orcid.org/0000-0002-2129-7443)
- Jingsong Lu (ORCID: https://orcid.org/0000-0003-3874-9108)
- Liheng Zhou (ORCID: https://orcid.org/0000-0002-2316-7773)
- Yaohui Wang (ORCID: https://orcid.org/0000-0003-0153-4277)
- Xueqing Zhang
- Yingying Zhao
- Yanping Lin
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1080/07853890.2024.2409343
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Rising-Star Program
- Renji Hospital